Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Информированные моделью стратегии приоритизации вакцины против COVID-19 по возрасту и серостатусу
2021-01-21
SCID: 54.1/nvwzadf7
Discuss with AI
COVID-19 vaccine prioritizationage-stratified prioritizationmathematical modeling of vaccine strategiesserostatus-based allocationtransmission-blocking vaccine
Figures from the paper
Abstract (AI)
Abstract When a vaccine for COVID-19 becomes available, limited initial supply will raise the question of how to prioritize the available doses and thus underscores the need for transparent, evidence-based strategies that relate knowledge of, and uncertainty in, disease transmission, risk, vaccine efficacy, and existing population immunity. Here, we employ a model-informed approach to vaccine prioritization that evaluates the impact of prioritization strategies on cumulative incidence and mortality and accounts for population factors such as age, contact structure, and seroprevalence, and vaccine factors including imperfect and age-varying efficacy. This framework can be used to evaluate and compare existing strategies, and it can also be used to derive an optimal prioritization strategy to minimize mortality or incidence. We find that a transmission-blocking vaccine should be prioritized to adults ages 20-49y to minimize cumulative incidence and to adults over 60y to minimize mortality. Direct vaccination of adults over 60y minimizes mortality for vaccines that do not block transmission. We also estimate the potential benefit of using individual-level serological tests to redirect doses to only seronegative individuals, improving the marginal impact of each dose. We argue that this serology-informed vaccination approach may improve the efficiency of vaccination efforts while partially addressing existing inequities in COVID-19 burden and impact.
Key Findings
1
A transmission-blocking SARS-CoV-2 vaccine prioritized to adults ages 20–49 minimized cumulative incidence.
2
Prioritizing adults over 60 minimized mortality and years of life lost in most scenarios.
3
Redirecting doses to seronegative individuals could potentially reduce existing inequities in COVID-19 impact.
4
The preferred prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and natural immunity estimates.
5
The presented mathematical modeling framework can compare impacts of vaccine prioritization strategies across different contexts.
6
Using individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact per dose.
Research Object
Age- and serostatus-stratified populations considered for COVID-19 vaccination prioritization
Research Subject
Effects of different vaccine prioritization strategies (by age groups and use of individual serological testing to target seronegative individuals) on cumulative SARS-CoV-2 incidence, mortality, and years of life lost
Publication Details
Publication Date
2021-01-21
Journal
Publisher
ISSN
Cited by
779
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest